437 related articles for article (PubMed ID: 19373949)
21. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.
Bacci G; Ferrari S; Bertoni F; Ruggieri P; Picci P; Longhi A; Casadei R; Fabbri N; Forni C; Versari M; Campanacci M
J Clin Oncol; 2000 Dec; 18(24):4016-27. PubMed ID: 11118462
[TBL] [Abstract][Full Text] [Related]
23. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
24. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
25. Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience.
Bacci G; Ruggieri P; Bertoni F; Ferrari S; Longhi A; Biagini R; Zavatta M; Versari M; Forni C
Oncol Rep; 2000; 7(5):1129-33. PubMed ID: 10948351
[TBL] [Abstract][Full Text] [Related]
26. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities.
Bacci G; Picci P; Pignatti G; De Cristofaro R; Dallari D; Avella M; Manfrini M; Marangolo M; Ferruzzi A; Mercuri M
Clin Orthop Relat Res; 1991 Sep; (270):87-98. PubMed ID: 1884564
[TBL] [Abstract][Full Text] [Related]
28. Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.
Min D; Lin F; Shen Z; Zheng S; Tan L; Yu W; Yao Y
Asia Pac J Clin Oncol; 2013 Mar; 9(1):71-9. PubMed ID: 22897971
[TBL] [Abstract][Full Text] [Related]
29. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999.
Bacci G; Ferrari S; Mercuri M; Longhi A; Fabbri N; Galletti S; Forni C; Balladelli A; Serra M; Picci P
Acta Orthop; 2007 Jun; 78(3):377-84. PubMed ID: 17611853
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life.
Bacci G; Ferrari S; Donati D; Longhi A; Bertoni F; Di Fiore M; Comandone A; Cesari M; Campanacci M
Oncol Rep; 1998; 5(5):1259-63. PubMed ID: 9683847
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
34. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.
Bacci G; Picci P; Ruggieri P; Mercuri M; Avella M; Capanna R; Brach Del Prever A; Mancini A; Gherlinzoni F; Padovani G
Cancer; 1990 Jun; 65(11):2539-53. PubMed ID: 2337871
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in non-metastatic limb osteosarcoma: A 20-year experience of one center.
Tomer G; Cohen IJ; Kidron D; Katz K; Yosipovitch Z; Meller I; Zaizov R
Int J Oncol; 1999 Jul; 15(1):179-85. PubMed ID: 10375613
[TBL] [Abstract][Full Text] [Related]
36. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
37. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
38. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
40. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
